Healthcare / Medical Instruments & SuppliesNSE
$1321.40
-12.50 (-0.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-620.2M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$134.1B
P/E
41.6x
↑EV/EBITDA
24.4x
↑ROE
10.7%
↑Gross Margin
68.2%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+19.1%
FCF CAGR
—
FCF margin
-3.3%
FCF / Net income
-0.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.75B · net income $3.31B · FCF $-620.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.75B | $18.75B | $16.70B | $13.66B | $11.09B |
| Net Income | $3.31B | $3.31B | $3.39B | $2.58B | $1.79B |
| EBITDA | $5.61B | $5.61B | $5.48B | $4.19B | $3.03B |
| EPS | — | — | 34.11 | 26.90 | 18.67 |
| Gross Margin | 68.2% | 68.2% | 66.7% | 55.8% | 54.1% |
| Operating Margin | 17.4% | 17.4% | 22.2% | 22.2% | 19.6% |
| Net Margin | 17.7% | 17.7% | 20.3% | 18.9% | 16.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.07 | 0.12 | 0.12 |
| Current Ratio | 3.37 | 3.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-620.2M | $-620.2M | $-979.8M | $-109.3M | $-482.2M |
| Returns | |||||
| ROE | 10.7% | 10.7% | 12.2% | 17.6% | 14.4% |
| Valuation | |||||
| P/E | 41.62 | 41.62 | 60.60 | 58.27 | 50.34 |
| EV/EBITDA | 24.40 | 24.40 | 37.77 | 36.32 | 30.23 |
| P/B | 4.31 | 4.31 | 7.42 | 10.24 | 7.27 |
| Growth & Yield | |||||
| Revenue Growth | 12.3% | 12.3% | 22.3% | 23.2% | — |
| EPS Growth | — | — | 26.8% | 44.1% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.9%
Start / end P/E
n/dx → n/dx
EPS bridge
34.11 → n/d
Residual
-42.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.